|MDACC Study No:||2006-0686 (clinicaltrials.gov NCT No: NCT00414310)|
|Title:||Phase II Randomized Study of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) with or without Valproic Acid in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia|
|Principal Investigator:||Hagop Kantarjian|
|Treatment Agent:||Decitabine; Valproic Acid|
|Study Description:||The goal of this clinical research study is to find out if decitabine, given |
with or without valproic acid, can help to control AML or MDS. The safety of
both treatments will also be studied.